Project description
A disruptive platform breathing fresh life into the cell line development process
Biologic medicines offer new therapy options for several diseases such as cancer. To develop and produce them entails a costly, lengthy and resource-intensive Cell Line Development (CLD) process whereby a high producing clone is selected from a cell line. Currently, clone selection is based on their product titer which can cause complications later in production. The EU-funded iLCA project will validate the technical and economic performance of its innovative technology solution for CLD - an intelligent Live Cell Analysis platform which provides end-users with a manufacturability index containing detailed information on their clones. The project aims to deliver an industry-endorsed analytical solution for the CLD process.
Objective
The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire life‐cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- engineering and technology mechanical engineering manufacturing engineering
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences health sciences personalized medicine
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EC - Horizon 2020 Framework Programme
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IA - Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-FTI-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
V94 DUBLIN 2
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.